Lenor 2.5 mg (Letrozole) Tablets

Lenor 2.5 mg (Letrozole) – Advanced Hormone Therapy for Breast Cancer

Overview

Lenor 2.5 mg is a premium formulation of Letrozole, a potent nonsteroidal aromatase inhibitor specifically designed for the treatment of hormone-dependent breast cancer in postmenopausal women. Manufactured by Eskayef Pharmaceuticals Ltd., this advanced therapeutic option has become a cornerstone in breast cancer management protocols worldwide.

Available through Saif Pharma, a leading global distributor of oncology medications since 2014, Lenor represents the gold standard in accessible hormone therapy treatments. This medication has revolutionized breast cancer management by providing targeted action with minimal systemic effects, offering patients improved survival outcomes and enhanced quality of life.

Mechanism of Action

Lenor works through a highly specific biological pathway, inhibiting the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit. This precise mechanism results in:

• Significant reduction of estrogen biosynthesis in all tissues
• Deprivation of growth stimulus to estrogen-dependent breast cancer cells
• Suppression of peripheral and malignant tissue estrogen production
• Blockade of the conversion of androgens to estrogens

In postmenopausal women, where estrogens are primarily derived from the action of the aromatase enzyme converting adrenal androgens to estrone (E1) and estradiol (E2), Lenor’s targeted inhibition provides powerful therapeutic effects without disrupting other hormonal pathways.

Pharmacological Profile

Potent Estrogen Suppression

Clinical studies demonstrate Lenor’s remarkable efficacy in suppressing estrogen production:

• Single doses of 0.1-2.5mg suppress serum estrone and estradiol by 75-78% from baseline
• Maximum suppression achieved within 48-78 hours
• Daily doses of 0.1-5mg suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 78-95%
• No effect on plasma androgen concentrations, preventing androgenic side effects
• No impairment of adrenal steroidogenesis observed

Favorable Pharmacokinetics

Lenor demonstrates excellent pharmacokinetic properties that contribute to its clinical efficacy:

• Rapid and complete absorption from the gastrointestinal tract (99.9% bioavailability)
• Food has minimal impact on absorption, allowing flexible administration
• Moderate plasma protein binding (approximately 60%, mainly to albumin)
• Significant concentration in erythrocytes (about 80% of plasma levels)
• Terminal elimination half-life of approximately 2 days
• Steady-state levels achieved within 2-6 weeks of daily administration

Therapeutic Indications

Lenor 2.5 mg is indicated for multiple breast cancer scenarios in postmenopausal women:

Primary Indications

• Adjuvant Treatment: For hormone receptor-positive early breast cancer in postmenopausal women
• Extended Adjuvant Therapy: For early breast cancer (positive or unknown estrogen/progesterone receptor status) following 5 years of adjuvant tamoxifen therapy
• First-Line Treatment: For hormone-dependent advanced breast cancer in postmenopausal women
• Second-Line Treatment: For advanced breast cancer in women with natural or artificially induced postmenopausal status who have previously received antiestrogen therapy
• Pre-operative Therapy: For localized hormone receptor-positive breast cancer to enable breast-conserving surgery in women not originally considered candidates for this approach

Dosage Administration

Lenor features a straightforward dosing regimen that enhances patient compliance:

• Standard Dose: 2.5 mg once daily
• Duration in Adjuvant/Extended Adjuvant Setting: Continue for 5 years or until tumor relapse
• Duration in Metastatic Disease: Continue until tumor progression is evident
• Elderly Patients: No dose adjustment required
• Hepatic/Renal Impairment: No dosage adjustment needed for moderate impairment; close supervision recommended for severe hepatic impairment (Child-Pugh score C)

Lenor may be taken with or without food, enhancing convenience for patients undergoing long-term therapy.

Clinical Safety Profile

Drug Interactions

Lenor demonstrates minimal clinically significant drug interactions:

• No significant interactions with cimetidine, despite it being a known inhibitor of cytochrome P450
• No clinically relevant interactions with warfarin
• Low potential for drug-drug interactions due to its specific metabolic pathway

Contraindications

Lenor is contraindicated in:

• Known or suspected hypersensitivity to letrozole or other aromatase inhibitors
• Pregnancy and lactation
• Pre-menopausal women
• Severe hepatic dysfunction

Side Effect Profile

While generally well-tolerated, patients should be aware of potential side effects:

Common effects include:

• Hot flushes
• Increased cholesterol levels
• Fatigue and increased sweating
• Bone and joint pain (arthralgia)
• Mild gastrointestinal disturbances (nausea, vomiting, constipation)
• Headache and dizziness

Less common effects include:

• Bone mineral density reduction (osteoporosis)
• Peripheral edema
• Mild depression
• Weight changes
• Hair loss
• Hypertension

Careful monitoring and supportive care can help manage these effects while maintaining therapeutic benefits.

Special Populations and Considerations

Pregnancy & Lactation

Lenor has demonstrated teratogenic effects in animal studies and is contraindicated during pregnancy and lactation. Women of childbearing potential should use effective contraception during treatment.

Hepatic & Renal Function

• No dosage adjustment necessary for moderate hepatic dysfunction
• Renal impairment (creatinine clearance: 20-50 ml/min) does not affect plasma concentrations
• Potential for removal by dialysis due to weak plasma protein binding

Patient Advisory

Patients should be informed that Lenor may occasionally cause fatigue and dizziness, potentially affecting activities requiring mental alertness such as driving or operating machinery.

Product Quality and Availability

Lenor 2.5 mg is manufactured by Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh with over 31 years of experience producing world-class medications. As part of the respected Transcom Group, Eskayef adheres to stringent quality standards throughout the production process.

Saif Pharma distributes Lenor to more than 60 countries globally, including the United States, Canada, Saudi Arabia, UAE, China, India, and Pakistan. As a specialized oncology medicine platform established in 2014, Saif Pharma is dedicated to providing high-quality, affordable cancer treatments to patients worldwide.

Storage Recommendations

To maintain optimal efficacy, Lenor should be:

• Stored below 30°C
• Protected from light and moisture
• Kept out of reach of children

Conclusion

Lenor 2.5 mg (Letrozole) represents a significant advancement in hormone therapy for breast cancer, offering postmenopausal women an effective treatment option with a manageable side effect profile. Its precise mechanism of action, favorable pharmacokinetics, and established clinical efficacy make it an essential component of modern breast cancer management protocols.

Through the combined expertise of Eskayef Pharmaceuticals in manufacturing and Saif Pharma in global distribution, Lenor is accessible to patients worldwide who require this life-changing medication. For healthcare providers and patients seeking effective hormone therapy options, Lenor 2.5 mg provides a well-researched, clinically proven solution backed by years of therapeutic success.

For more information about Lenor 2.5 mg or to place an order, visit Saif Pharma at www.saifpharma.com or contact Eskayef Pharmaceuticals at www.skfbd.com.